N
Google TrendCOVENTRY VS NEWCASTLE (2000+) — Premier League LIVE: Coventry City vs Newcastle United - build-up, team news, score, text commentary & match stats
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:coventry vs newcastle2000+levante - sevilla2000+servicio de control de inmigración y aduanas1000+indigo girls200+afc champions league200+essie fall nail polish trends 2026200+geomagnetic storm aurora visibility northern us500+matthew stone sr500+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "First US Patient Treated" (30 stories)

Top Headline Story

TISSIUM® Announces First U.S. Patients Treated with the ECLIPSIUM® System in UNITE Clinical Trial
Lead StoryGlobeNewswireworld
6d ago

TISSIUM® Announces First U.S. Patients Treated with the ECLIPSIUM® System in UNITE Clinical Trial

<a href="https://news.google.com/rss/articles/CBMi-gFBVV95cUxPU01uNjkzTGRNZFpaUjlRWWJ6d0M5U0NzWHM3bnJqS0Nkb1Vla01XTFg2aXMxbHF5dUF4ek1zSG1zX0kzbVVVbjVlT3MzaUJvY1hIaXhJajMtcEs2bkUzbEJBUTJNSC1sWDVVTUswd1JWV01JR1NSSk1SZmVvaERWWVVBNGhabE5SbU9kblNoZGRWYkY2UXR3ajdNTU51OW53V1VWSHM4bmtURHZiNzc1bjQyUEUwT2xkNHlKOWdXYl9lZTZOSHJtU01RMzZRTEt4WG1ZQWJYMTRQRWhLWWJCWkdwOXo5Rks4eFAyS2JkazNoZ09sMHRqeGpn?oc=5" target="_blank">TISSIUM® Announces First U.S. Patients Treated with the ECLIPSIUM® System in UNITE Clinical Trial</a>  <font color="#6f6f6f">GlobeNewswire</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
2000+19m ago

coventry vs newcastle

Premier League LIVE: Coventry City vs Newcastle United - build-up, team news, score, text commentary & match stats

Filter stories
2000+19m ago

levante - sevilla

Levante - Sevilla en directo

Filter stories
1000+19m ago

servicio de control de inmigración y aduanas

"La cosa se está poniendo tensa": manifestantes se enfrentan a agentes migratorios en Oregon

Filter stories
200+19m ago

indigo girls

Indigo Girls cancel show after tour bus driver dies in highway crash

Filter stories

Search Results for "First US Patient Treated"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
First RAS Inhibitor Extends Survival in Previously Treated Metastatic Pancreatic Adenocarcinoma: What You Need to Know
Pancreatic Cancer Action Networkgeneral

First RAS Inhibitor Extends Survival in Previously Treated Metastatic Pancreatic Adenocarcinoma: What You Need to Know

<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxQQ3pGR2lUVEZuRWZ6ak81R3RtMFFndU9EVG80ei12Sm53cnVpREJtOGUtclhJUGhEWklDaE04dlJBazV0UTQwOXd0NHdSTTVpbUYyQWZQZHR4RUN5S1kyQ1RfUkVmOE5jQ1BFRW03U043MV95UUhycEFITm5NZFEwc3UyaC1Odm95WWprbWdVcWw4Rmh0ZEZNejlvWUxhdmllaGZickJ0WmxBeXNielRHR2x3RUQ4MHBRam5oaG1xRXMyY3NoMHVuYnRHS2prRDJfY1hIeVd6TFY4dw?oc=5" target="_blank">First RAS Inhibitor Extends Survival in Previously Treated Metastatic Pancreatic Adenocarcinoma: What You Need to Know</a>  <font color="#6f6f6f">Pancreatic Cancer Action Network</font>

Read Full StoryMore like this
UC Davis Medical Center first in U.S. to treat heart valve condition with investigational device
UC Davis Healthgeneral

UC Davis Medical Center first in U.S. to treat heart valve condition with investigational device

<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxQRktOU2lSY0N3Nko0UU9PdjZLQ01YT1lyM00wYzRaQkNrUTg3bHNreGNldE0wUGl4eE14OEx5V2JEWEptbm5FaW8yeGg0Rk9rRTZyVy0tTmhveTAxNjctbmZBZzk5OTRxLUJONlliaGZnMzZTRldVeDVZOVB0Y0lxSDJSemFvUTJBbC1iTnhtM0hjakJxM1B2Yk9kSXpVZlUxbjg2VWFpR2NVRm9PWVUtblN2UHYzbEJtWTVIUFl1Mzk4X3MwRkpDOTVYbEJrT1loOUhIbk95T2RHaUdy?oc=5" target="_blank">UC Davis Medical Center first in U.S. to treat heart valve condition with investigational device</a>  <font color="#6f6f6f">UC Davis Health</font>

Read Full StoryMore like this
Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa)
Ultragenyxworld

Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa)

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxQY0cwS1JEdG8xZGZEelNuV2hTcmNYZGxkbS1mRnd0eDhPVDBIQzVRMVFXbHVSRWp3d2ZZQ0ctR0VpMTkzakJ3VU1ma204TFppZmdZSmhJU3dkSE9FS0t4VmhrNDYzMGRIQ25QaE1zdVoyTy1SRWl5SWt5WkNJSzBPV1o5VlFKZ1ZZVHhWNkQ3dUVBM1BKRkNkeWNGbDFuWUROOFAzTW9qWFViUi0wdGN5T3I2OWtCUE9SQ2NYQS1QNA?oc=5" target="_blank">Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa)</a>  <font color="#6f6f6f">Ultragenyx</font>

Read Full StoryMore like this
VDyne Announces First Patient Treated in TRIVITA US IDE Pivotal Study of the TriNova™ Transcatheter Tricuspid Valve Replacement System
Business Wireworld

VDyne Announces First Patient Treated in TRIVITA US IDE Pivotal Study of the TriNova™ Transcatheter Tricuspid Valve Replacement System

<a href="https://news.google.com/rss/articles/CBMimgJBVV95cUxOaWM3VzlOUXBMeTJwUG5aZkpSS1pRYi0xTGhWR2NjS2ttMlViY1c0TTY2TFVwa1pVMHduWGs4bHZKUnJiNzRJS0FjNWVIaXh0a0g4cDRSNU1LMGFFMHItRGlEbEY1amJhWmx3TW4ySjJJbmFPMEdFNi1INGxkTjJiNU03ZEFuMVdXY0Q5blBsUFI3V3RGQ0txRHVjLWZCWExScDJ4emVKREE4eVJLN3BUb243TjN0QWpILVVkR2tLLUlpWVlzZUoxU3lWNnVYVHVIYk5NdVBDaVJBbENTdXpJU3dlOENjS2EtRUVBMWlid25aY0lpWERpbmVVZXhlMHUxQVJDaWNTWDNTN2dBNF9QRW9Tcm9TSkpnMFE?oc=5" target="_blank">VDyne Announces First Patient Treated in TRIVITA US IDE Pivotal Study of the TriNova™ Transcatheter Tricuspid Valve Replacement System</a>  <font color="#6f6f6f">Business Wire</font>

Read Full StoryMore like this
Med school enrolls first U.S. patient in global trial to treat childhood chronic kidney disease
Indianapolis Business Journalgeneral

Med school enrolls first U.S. patient in global trial to treat childhood chronic kidney disease

<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxQMHJNWXFZSkJEY3hvbmRNRDhXSW1BUk5laVp4TTc1Nk0yc2k1RGZRSm40WjREVnRYRVdLZW04ZmN5RlEwSHhGZjVUcEh1OEd6UlRnMkZ0SXhmTngwVEpmclVaUDg1X2hxbHNtOVVaZkFxazRJU2FnT0hEdXluX2Q0dDk2NmdpSGdWSEpXV3dfYmhQbEFnUGd0QmRFd3JIX0RfdWM5dmtBQjRib0c5aFN6SWlFNmMxSDBJU0hpMnFadHg?oc=5" target="_blank">Med school enrolls first U.S. patient in global trial to treat childhood chronic kidney disease</a>  <font color="#6f6f6f">Indianapolis Business Journal</font>

Read Full StoryMore like this
First US patient enrolled in device study to reduce coronary microvascular dysfunction
Cardiovascular Businessworld

First US patient enrolled in device study to reduce coronary microvascular dysfunction

<a href="https://news.google.com/rss/articles/CBMi7gFBVV95cUxPOFBIa2tBLW5Sd3lZSWFnd21WRW5qbllNY2JubDJrejZZc3BSaFdnR1F2anlDS2I5VENVbG1mY1lpeHduQXU5TlBaeHljVnRzYTFvTlRzUU1sVlJYNDlhUEZsc2FFWWc0ejJzUXp3dmpxWTFEX18tVU1NTUdlTmlDRFRORmdHdW1mZXJrRUhMT09PRzRQbGlyWUM4VTVEQVhIa2J5Y3FDUXNhNTA2Wml0TUxmREs4SWJUbE9HaFlpVWpCdVpsOWVUSUVmNXdaTTduaVU0d0JvUDZ1RVNaRklEeGZJWW1oMWpCcGx6Skh3?oc=5" target="_blank">First US patient enrolled in device study to reduce coronary microvascular dysfunction</a>  <font color="#6f6f6f">Cardiovascular Business</font>

Read Full StoryMore like this
Liverpool man becomes first U.S. patient to receive newly expanded Pluvicto treatment at AMP
WSYRgeneral

Liverpool man becomes first U.S. patient to receive newly expanded Pluvicto treatment at AMP

<a href="https://news.google.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?oc=5" target="_blank">Liverpool man becomes first U.S. patient to receive newly expanded Pluvicto treatment at AMP</a>  <font color="#6f6f6f">WSYR</font>

Read Full StoryMore like this
Servier Announces First Patient Enrolled in Phase Ib/II Study for the Treatment of a Rare Pediatric Epilepsy Syndrome in the U.S.
PR Newswireworld

Servier Announces First Patient Enrolled in Phase Ib/II Study for the Treatment of a Rare Pediatric Epilepsy Syndrome in the U.S.

<a href="https://news.google.com/rss/articles/CBMijwJBVV95cUxPN2hqNlNmaFVNaE5ZZXFsQjREUzRERTh0U1hYSlBpdUdoTVFuaTZpX2NaOGl0NmVHcjZQZTcyQjR4YmlmR1gweWk3UC01RXdGNE9Yc0p4NW45WHR0VW9abEYyR2ppMGotSEtIM3haUGg5UHF6MG9uWGx4bXN0bF9wT0UxQVctS280OFJ5UHdKNXdTQ1ozblR3a3hRbzA0YVlQRWh1Y2tHVTVLYVZhZk9OZmh0aWstdVUyb3pJbGoxeFhRcENUN0xwZmZUUWg5RnlsbEtIUTFGNzRNUUtiNzRSQzhXc3dyUjJGM1l2SmJaMjBYbElfM2ZSU3Z2LW1MVVYwTm1YQnRyc1ZESld2akpJ?oc=5" target="_blank">Servier Announces First Patient Enrolled in Phase Ib/II Study for the Treatment of a Rare Pediatric Epilepsy Syndrome in the U.S.</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
First U.S. Patients Treated With Microrobotic Surgery For Alzheimer’s
Forbesgeneral

First U.S. Patients Treated With Microrobotic Surgery For Alzheimer’s

<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxOeVdrOXZTUmxzUkg3dTFXV2pXYjgyN3F3WFJneElvb19WYUFwcnRGbEdLRE0zNFh5bjhDbnBWb2FGNlBLSWNUMVN1VmFBckMxMno5SDVnU2R5QmpJWW05dFU0QXJTakV2a014VEJZQUc5ZHF5OTFpWHREX3ZDczl6UWVzOFdCU3F4dFVfYWF5U2ctN0JnY2dhb1h1bFNXVzBJS2UzZjBPcXlhQXRNN05aNm1GdnJjN2daZ1Y5ZA?oc=5" target="_blank">First U.S. Patients Treated With Microrobotic Surgery For Alzheimer’s</a>  <font color="#6f6f6f">Forbes</font>

Read Full StoryMore like this
Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma
Alpha Tau Medicalgeneral

Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma

<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxPbUhlVWlNejJ0ZXhQZlJsYlh3cFhXQTYxRFNxakdRX3NUSndkZFIybmJPM1FnVkotOGtsV1hjQ3JwZU5PNUJmMkNoQm1abm9VSUJJVkVWbWJQbHktSnJQUnQ3MEZnN2NiVjRqdjR5U1pRa3d2MUNrUE1NdHA0cy1VSEJXZ2ptUldkbnFjbHJkcGFkUzV1SjdJRUZSRTU1U0g2MU1zYkd4NV9STnJVbzdxZXZCMmpHSEFjY09jVjE3bnA4NVY2Vlh0RFRVajN6U0YyaVdlem1hVzR4dWs?oc=5" target="_blank">Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma</a>  <font color="#6f6f6f">Alpha Tau Medical</font>

Read Full StoryMore like this
Sumitomo Pharma America Announces First Patient Receives Treatment in Phase 1/2a Study for its Investigational Therapy DSP-3077 for Retinitis Pigmentosa
BioSpaceworld

Sumitomo Pharma America Announces First Patient Receives Treatment in Phase 1/2a Study for its Investigational Therapy DSP-3077 for Retinitis Pigmentosa

<a href="https://news.google.com/rss/articles/CBMinAJBVV95cUxQWGhlY3NDOTJrZ2tld3R6UlhLTEh5TkdiTnNrUzNGcVNYUDB2aVJXUWRZM3kzNFZTWVFqNWdzWXlkS29ZT1VvUFUzcmNNOFVfR1BWU0R1SW43ZFRHRWQ2RWVsUUZJMXFNeFFXdE5vVEoxZ1QyblY4aUxad2ZEcUVPeFBJQ0R5UzhyUDlYc3c0VDV1b3RycVVEVDB3aEpHaFNWNEsyc2V0bHBCYjM2YTFNbExBbzR5RVgyUVFZLVBjZjVEYTc5OXRXSTBlT2wyRlJsY3p6VWRtUGJNZWtMeVY3SWxRbUpEUGNFNGFRaDVSaFNURHNZUW1GRVZJR1Z4YVA1cU9OdHBXaG5PRTBFWklVNGw4a3d1bThzc2hTMA?oc=5" target="_blank">Sumitomo Pharma America Announces First Patient Receives Treatment in Phase 1/2a Study for its Investigational Therapy DSP-3077 for Retinitis Pigmentosa</a>  <font color="#6f6f6f">BioSpace</font>

Read Full StoryMore like this
U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
Gilead Sciencesgeneral

U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer

<a href="https://news.google.com/rss/articles/CBMi8gFBVV95cUxNUHlYa3R3c0ZFMkVvYWFOaTVLLVFXSC10TDI4SHJhMWVuN0dOVVZ4RmlvS3VKRkwtY2tCSkJ5Rnk0R2J6dktpT29lWEdMbWZpeUdzdTNuUm5rVlhkbW42amdKNWt0ZWdtUkpaU001ZVRmZkFKaUFjOUpheWVIa3hLbVhWTmsxR2hqN0lLY3YwUWdIbExKMEFkRFlUb19WazhYbmxJTlc1eHVtTEtPOFZjUWs5YnJDakUxMnVSd1dFNTZBZVZqRlMxT3VvVUhmeXhIUk5TUEpwVDhUMEI5cG5JTzBmZ3NPc3pCVWg1NVpLVVM4Zw?oc=5" target="_blank">U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer</a>  <font color="#6f6f6f">Gilead Sciences</font>

Read Full StoryMore like this
Anteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial
Yahoo Financetech

Anteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial

<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxPbVJSVGlBRHRPZlZNZnQ2Y082Z3p5UFFQZ05pUTZqeEpuTGxOTUVoSHlTNk1RU09ERy1YdUFmVzhUcjFqMmZ1TjFsakN2dlZBOElLT1JMcmlCbFNieVBLSHdsOVAweERUQ2ZLb0tJMzdJTjhtWFV2Ql9hc3NUN1ZhOVRseHd4d3hNeTlhX3FSR19fVldvZHNjUDdnNUVLOUoyQ2NqQ1JhM3dmYjA?oc=5" target="_blank">Anteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial</a>  <font color="#6f6f6f">Yahoo Finance</font>

Read Full StoryMore like this
VahatiCor Enrolls First U.S. Patient in SERRA-I Clinical Study of A-FLUX Reducer System® for CMD
PR Newswiregeneral

VahatiCor Enrolls First U.S. Patient in SERRA-I Clinical Study of A-FLUX Reducer System® for CMD

<a href="https://news.google.com/rss/articles/CBMi4wFBVV95cUxPWFFsam5wZFBOeGcyVWl3Rk5ZTTdnbl9waVJWVzltVkVpRnZVcHRJNExrQ0FEWE9ERktMUUswczNLckhBN1dSam5EeTZaMFYtbGgtTjBtQWQ0U01VU1hGZEZwSHJJVnAzZ1dNcjNoOHFJRzJNRlBmYWQwdW90TDljS09MdFhKallxMk5Nb3d0YWp6LURDUlBhaTlmbDFmWFN1bFhDYURlWkphMlRaMVRQMm43VVltaGZwVThLUVFJNjQ5QWlyb01qdjZ5VERURm9DLW5qa2lENTlYdHlqZnBXa3p3MA?oc=5" target="_blank">VahatiCor Enrolls First U.S. Patient in SERRA-I Clinical Study of A-FLUX Reducer System® for CMD</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis
GlobeNewswiregeneral

First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis

<a href="https://news.google.com/rss/articles/CBMi8wFBVV95cUxPSkoxM1J5NzVoNGtyZzJXVUpoZXh2Um0xanRYTjh2d2ZLSVN5WGlsMmlFSjJaNy1jV2t0WkowSnhibHM1UUU5YkZpam5QMU80RFV4c2w3ajJ2U3VBd0t2Uk9PU19hWk1vYkFnT1JrOTdzMGY0UlRDRkZFNjJiTWhmWm9nU1BIUGpaUmczVjBEWGwyOXBEZVVTVFFaX3d5VWFuMmNCeVRWTm9COFhYX3lMeTVwbjB1Y1BPc1FMeWVGOUZ4THB0aWtpUzRBTGZ0c0dqdE5yUjNYMkZSaG9GSE4wVnJRMXNJSmV2SEFibm1GVjM1dUk?oc=5" target="_blank">First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis</a>  <font color="#6f6f6f">GlobeNewswire</font>

Read Full StoryMore like this
Annexon Reports First U.S. and European Patient Cohort of
GlobeNewswireworld

Annexon Reports First U.S. and European Patient Cohort of

<a href="https://news.google.com/rss/articles/CBMi5AJBVV95cUxORUNxWFBkdVFuX0xjd19URVhGLVNTSi1nU2RNSmdncFd1Q1ZUSDlGczR5SzIyMEdjLTNrV2tsM01CZ0hBUTZjY2VCckRiSmphNVVhM05rVzhkRXdhZ0R0OHMtSV91WVJick1XYzY1Q3doQW9DcmxoS0NZRGVpdFBDUHU5VndodWZLVVltcGdUQzlIRmYxRVlBUGRSTU9JOENyeTAwcTNPNENIWEstTEVCUFUzZXY0Y1lVWUFhZnJsRzBnYlM1THFPd1ZBZG5lZG5wbkNvQ2F3ZnAwVTh4ZUh1VkxoeVFZZzIxTjdwZzhNamhvU0s1SlJ3SVlnNGwxTzFSeHNIUjN1aWd6Sl84emk3NXdHMTdHZ0k4bHpFRGtoQmNjNUF5VTBMUDhJTEU0ZGJkT2ZqSmduck14b3JpWE5DUE5nRjFkcFZSaEtMcm9QbGozMTlqZWNtUE1Qckp3cEYxOFlZRw?oc=5" target="_blank">Annexon Reports First U.S. and European Patient Cohort of</a>  <font color="#6f6f6f">GlobeNewswire</font>

Read Full StoryMore like this
Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
GlobeNewswireworld

Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts

<a href="https://news.google.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?oc=5" target="_blank">Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts</a>  <font color="#6f6f6f">GlobeNewswire</font>

Read Full StoryMore like this
First patient treated in Airiver Medical’s RESTORE-2 trial for CRS
Medical Device Networktech

First patient treated in Airiver Medical’s RESTORE-2 trial for CRS

<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxPQWY3V3pJNVU4TUtBWWxHbGhtT2Z3dWpsSjJVVWVmSmhVSHZ3RnNJeWNGN214LWR6a2tWdmtjUkpKWmQ0Z19WQnFnU2dnZGIyOUdfaWE2YzVrVUlaREd5T1lEMWswY2U1TFZUZjlPRHNtT2pja2I0YmU1d3cxdnVEc3U4N3ZNbWNPX3ViT0pBemhHOGM?oc=5" target="_blank">First patient treated in Airiver Medical’s RESTORE-2 trial for CRS</a>  <font color="#6f6f6f">Medical Device Network</font>

Read Full StoryMore like this
First patient treated in US study evaluating robotic-assisted microsurgical intervention for neurodegenerative disease
NeuroNews Internationalgeneral

First patient treated in US study evaluating robotic-assisted microsurgical intervention for neurodegenerative disease

<a href="https://news.google.com/rss/articles/CBMi6gFBVV95cUxQUjRnNzRuWktrdHkyZ3F1OUgzVl9sTVNSUERNTU14NHZkYklKbXJqRWNqeVk2QmsyRjdFU2NzNTFDamNYaGcybV9kWlZzSk1GOFphZUIwUTZYbDNZMFZVQ3paQU9Mb2w2OTBPSTBsNHZaWUxZVXg5MHU0cE1OYWNvNW9LcUlSdE5EWndCZVI5U3BoRHRvS0d5NHlpUmxjaEdTaXFkODNTUkNGbkVQRkFScVhURmttdURCNi04VFp4VjVwTGVYdFRiVE84d2lka1h5aVJRRk5FcE1TRUM5MF90bGw4dWpyZThWeGc?oc=5" target="_blank">First patient treated in US study evaluating robotic-assisted microsurgical intervention for neurodegenerative disease</a>  <font color="#6f6f6f">NeuroNews International</font>

Read Full StoryMore like this
Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
Business Wiregeneral

Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates

<a href="https://news.google.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?oc=5" target="_blank">Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates</a>  <font color="#6f6f6f">Business Wire</font>

Read Full StoryMore like this
Arialys Therapeutics Announces First ANRE Patient Treated with ART5803 in Open-Label Phase 2 Study and FDA Clearance of IND for Randomized Phase 2 Study
Business Wireworld

Arialys Therapeutics Announces First ANRE Patient Treated with ART5803 in Open-Label Phase 2 Study and FDA Clearance of IND for Randomized Phase 2 Study

<a href="https://news.google.com/rss/articles/CBMiswJBVV95cUxPQmxEQjhWd3lUSXBteWszQkU2WE1ZQmc5UzVtUUlkZk5ZZ0o4YVMwZ1JhQlJmcjFnSGZvbnZxVXR6Y1BKRTV1M24zVlUzVG12WmFfUnlKeXBBd2R0VURiR19IYmJDbEExYVJlR0VySUxFWlVfNTg2QzJjMEpjczI0OWRJVEhTMTFQN3FXaS1VcmNJSFNWUUtob0FZMnBqMmpBOGtlSnRiZGdYa3lFVTJzLXRFVDN3LVo2MjdQZ25PZ29sVFJ2NVF5WG93OWVVTXliNTQ2OUJudXlvS1lPU2s1NHBibzdVaWRGcTh3RkpCb2RIa19uUkxrRlhWU2ZlTmJ5SS1idmZOdmU3MHdSR1VQdEFKcUd0VEJpb0xrRE1JVkpxQU9nbU5ERjcza1hFSGE5WTc4?oc=5" target="_blank">Arialys Therapeutics Announces First ANRE Patient Treated with ART5803 in Open-Label Phase 2 Study and FDA Clearance of IND for Randomized Phase 2 Study</a>  <font color="#6f6f6f">Business Wire</font>

Read Full StoryMore like this
AOP Health US Marks First Patient Treated with Rapiblyk® in the United States, Expanding Access to Critical Care Innovation Nationwide
Business Wirescience

AOP Health US Marks First Patient Treated with Rapiblyk® in the United States, Expanding Access to Critical Care Innovation Nationwide

<a href="https://news.google.com/rss/articles/CBMimAJBVV95cUxQdm1YVkRQbXJ3aU9jbmJmanpyMkJHblRsdHpFTkhCS3AyanR4UDJxSDJPQWY1bWRCRGN4NWU5bWs3ZjBNOFBTZXJpbDZrRlltcWxaUHVHeGUyamdQSFJGd241cVNibTlsMnlxMVU3R0FuVklGMmdDd2d2LWZWaHhaWFk2a0hOVTlzd1FqbTJsLVZqNW9SSGlvbVpNNmZkZVRDUUd5UzZFc2p0dUVWeU9TczU2TExGdkF3Wk0wZFFpSHlWMUh3QWZ3d0RtNGlIUzI1YmcxUFVuZjZQZ3JkUUNheTZiR0p1SWlNUUpKeU1FRHo0Z09MMHZoWGlLWlBGQmpuQlM0S2tYRHFYenV3STN6VlRpMUNaczdK?oc=5" target="_blank">AOP Health US Marks First Patient Treated with Rapiblyk® in the United States, Expanding Access to Critical Care Innovation Nationwide</a>  <font color="#6f6f6f">Business Wire</font>

Read Full StoryMore like this
Anteris reports first patient treated in pivotal heart valve trial
MassDevicegeneral

Anteris reports first patient treated in pivotal heart valve trial

<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxPNHVTUVF1LV9UclRXR1BrbGswTThDSjFDb2tpM1BEWWpHQ0VnYU9zdFZIQl9saGpNQ3ByZ3hlNjVNT0VoRHN5ZHhYRGYyaXRET0FVaVFOcGtIVVhIc3RPcnozYmVGdm1RSW56elpyVGhiWkFlcDNtUUxOSEVHWUlmVQ?oc=5" target="_blank">Anteris reports first patient treated in pivotal heart valve trial</a>  <font color="#6f6f6f">MassDevice</font>

Read Full StoryMore like this
Dubai’s Medcare Hospital Becomes the World’s First to Treat an Adult Spinal Muscular Atrophy (SMA) Patient Outside the US
Business Wiretech

Dubai’s Medcare Hospital Becomes the World’s First to Treat an Adult Spinal Muscular Atrophy (SMA) Patient Outside the US

<a href="https://news.google.com/rss/articles/CBMihAJBVV95cUxNb2pDSlpQRVVSZTVrcmpfcDlZN2xuc0JxZThYUS1VNERZQkZrTXRLbWU1UDNNMXdnQ213ODk5elUtTFZDM1JndVdoZVZGZk5najRPVXVFaGRtRTNLTUhXZURWSXdvUFl2M2FsSjh0M1ZPSkhxRTVZUTd6N2JOX0FtbmQ3RFpyR05yaGNDeWVwTUFzcE8tMkJNNV9saDRBVHJsM0NlODV4Nm5tTC1hcWI4b1REaGFFODlsam5xVjRVRmZ3aXo3SVBETDVGWDVDQUVlT0UteUhHX1AtN2NMSWhQQTRoVTAwNGk2MmVBNXVmeHk0ZUppSVFUdWp1MnlaYS1SdEVqQw?oc=5" target="_blank">Dubai’s Medcare Hospital Becomes the World’s First to Treat an Adult Spinal Muscular Atrophy (SMA) Patient Outside the US</a>  <font color="#6f6f6f">Business Wire</font>

Read Full StoryMore like this
First US Patient Treated with New Lung Cancer Therapy
Respiratory Therapyworld

First US Patient Treated with New Lung Cancer Therapy

<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxPcEtOM21UZWYtbGd4am9NU1pqSGJVY0VFYXFJUWFrOHQtWEhYcjNMWFN1XzJ5cTBSeWlhd0JaUkF1akhCYmJ4LVRxQ055YlpfaTliQmtJQ0s1TzlDeUgwbDI3UXQyOS1UNWRkdWhRNTlfdmc3MWd2VS1zSEpUaThfY0hGMDQyUU96VTdSaFg2THk3Y2xManQ3ckNsRURTXzBRS1JDMkxaSDJfaXVjSy1jd2NjQ1VMV29ibENmYVlSaVN6UWxmT2E5ZlU4SnJ1RnFVS3J3?oc=5" target="_blank">First US Patient Treated with New Lung Cancer Therapy</a>  <font color="#6f6f6f">Respiratory Therapy</font>

Read Full StoryMore like this
First U.S. Patient Treated With Alveltamig for Small Cell Lung Cancer
Cure Todayworld

First U.S. Patient Treated With Alveltamig for Small Cell Lung Cancer

<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxNRkNEdlBnQlJhXy1UbDNXaGxVTFdvVFIyWXc1UnBWRWxac3dHdDlCdjcxLWZxRUxMZkNCZ3JHUmVWdFFMdEZ4bFg2V1JGREdIUlk3QVhMQVRsUlREaG8xZjVCSUJjblVsUlNKUl9IbGU5aXI1VGVOWXNqZm5VU1R2MVNFTEdWcmdJTVFRZnhNX0R0UEpHUzJPN05kSnc3cEU?oc=5" target="_blank">First U.S. Patient Treated With Alveltamig for Small Cell Lung Cancer</a>  <font color="#6f6f6f">Cure Today</font>

Read Full StoryMore like this
First Three Patients Treated with Novel Theranostics Drug in First-in-Human Clinical Trial | Huntsman Cancer Institute
University of Utah Healthworld

First Three Patients Treated with Novel Theranostics Drug in First-in-Human Clinical Trial | Huntsman Cancer Institute

<a href="https://news.google.com/rss/articles/CBMi4gFBVV95cUxNVnB0ejJnTnZMa1MtUHpQS0V2ZUV4V3Z6OGZab3JwN01QdzB6OXMxN3B2T3ZWWldPUS1XenoxS0NMRFF0aFlfWW9XUjVWUHZkZF9TRERnU3BnZVdNUVJQLTRlM2FsNFJYWEJOVnFDMGp2UEFZc3htcUd1YzJuSHd3MWk4dVRhX0ltTEJlTkltRUhycWpzT0ZMVlY3YjAzQWxmYTg3VExPNlhjVk0yNEQwTnRXUlBZdG1INkRwUm5PSWg0Vk5RR0lIaGVMdmJXWHFYUmxtOE9JRVR1a0xRa0FwYU1B?oc=5" target="_blank">First Three Patients Treated with Novel Theranostics Drug in First-in-Human Clinical Trial | Huntsman Cancer Institute</a>  <font color="#6f6f6f">University of Utah Health</font>

Read Full StoryMore like this
Focused Ultrasound for Low Back Pain: First US Commercial Treatment Performed in North Carolina
Focused Ultrasound Foundationtech

Focused Ultrasound for Low Back Pain: First US Commercial Treatment Performed in North Carolina

<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxNdHVGY3RyMDl1ZmhsTmhQZXhRdVBSUHppRFlHTTZqQ01tUjVsSnpNc1lWd2pJbERDdGpmUnNWVHNkMVhCZHhUbUFwMy1URE4yX1RhV1VjcGQ0SWtOclFpYjl5cVhRV3V5bmozWmVtOHR1ZTRuQjJHU2NSUWpTS0F2dDY5cnotTVlRVEliVnpzU2dyeFlFNlR4eENqQXVaamxveWhnbEZlaFl1dWVrRkFJT0hES2tyc0FoN1A4Q3pVVHU1cXlDaWV1bk1kaw?oc=5" target="_blank">Focused Ultrasound for Low Back Pain: First US Commercial Treatment Performed in North Carolina</a>  <font color="#6f6f6f">Focused Ultrasound Foundation</font>

Read Full StoryMore like this
Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University
Alpha Tau Medicalworld

Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University

<a href="https://news.google.com/rss/articles/CBMijgJBVV95cUxPVkx6cXp3bWhXVjR3Z3ZzSFUtSy1JV1lMem1xdEhJeWRHbEwxTVcxSThaclZvMTJjRUF2cDkxbmNPNFJ6MVRGVGlYNWk4U21iR1RYdk1HQWRPWlh3MW1uS1ZfbVFHdnh1TndqTzNhZDgtSDFzXzBVT3M1UHhINzJPcjVfVFdBcHNhNEFVRkt1OGtyRUlRTWVYUU9tQTRBYlNwR0REY0NTcnh0YkkxN2d0VkpKbzFUNEhYWmNFQ1lUSnpNdnlpUzdsM0hRV3hZcUw5NldIbVQ1SDg4bVpzY0Zyc1hfR2prWjVSTjNOZFNLdnh0Rk8zTUQxZHFFdGJZZmlBRWE3TUdNQmRVR1pPd0E?oc=5" target="_blank">Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University</a>  <font color="#6f6f6f">Alpha Tau Medical</font>

Read Full StoryMore like this
"First US Patient Treated" — Live Google News Trends & Headlines